Adherence to denosumab therapy and fracture risk associated with drug withdrawal: a retrospective study.

IF 2.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Croatian Medical Journal Pub Date : 2025-10-31

Hande Özdemir, Nur Kakilli, Filiz Tuna, Buket Yılmaz Bülbül, Mehmet Çelik, Selçuk Korkmaz, Derya Demirbağ Kabayel

{"title":"Adherence to denosumab therapy and fracture risk associated with drug withdrawal: a retrospective study.","authors":"Hande Özdemir, Nur Kakilli, Filiz Tuna, Buket Yılmaz Bülbül, Mehmet Çelik, Selçuk Korkmaz, Derya Demirbağ Kabayel","doi":"","DOIUrl":null,"url":null,"abstract":"Aim: To assess the prevalence of fragility fractures after denosumab discontinuation and to identify the factors affecting treatment adherence.Methods: We retrospectively reviewed the medical records of 3876 osteoporosis patients who were treated with denosumab at Trakya University Osteoporosis Clinic between 2015 and 2021. A total of 210 patients who received at least two regular doses of denosumab were eligible for inclusion. Patients were categorized as denosumab-adherent and denosumab-non-adherent. Adherence was defined as receiving the six-month scheduled dose with a maximum delay of up to eight weeks.Results: Overall, 124 (59.05%) patients were denosumab-adherent and 86 patients (40.95%) were denosumab-non-adherent. New fragility fractures were identified in 32 patients: 17 in the denosumab-adherent group and 15 in the denosumab-non-adherent group. The groups did not significantly differ in the risk or types of new fractures, irrespective of patients' fracture history.Conclusions: Our findings suggest that some fractures after denosumab discontinuation may stem from the natural progression of osteoporosis rather than from the rebound effect. Still, unscheduled treatment discontinuation should be prevented.","PeriodicalId":10796,"journal":{"name":"Croatian Medical Journal","volume":"66 5","pages":"334-344"},"PeriodicalIF":2.3000,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12623255/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Croatian Medical Journal","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess the prevalence of fragility fractures after denosumab discontinuation and to identify the factors affecting treatment adherence.

Methods: We retrospectively reviewed the medical records of 3876 osteoporosis patients who were treated with denosumab at Trakya University Osteoporosis Clinic between 2015 and 2021. A total of 210 patients who received at least two regular doses of denosumab were eligible for inclusion. Patients were categorized as denosumab-adherent and denosumab-non-adherent. Adherence was defined as receiving the six-month scheduled dose with a maximum delay of up to eight weeks.

Results: Overall, 124 (59.05%) patients were denosumab-adherent and 86 patients (40.95%) were denosumab-non-adherent. New fragility fractures were identified in 32 patients: 17 in the denosumab-adherent group and 15 in the denosumab-non-adherent group. The groups did not significantly differ in the risk or types of new fractures, irrespective of patients' fracture history.

Conclusions: Our findings suggest that some fractures after denosumab discontinuation may stem from the natural progression of osteoporosis rather than from the rebound effect. Still, unscheduled treatment discontinuation should be prevented.

Abstract Image

本刊更多论文

依从地诺单抗治疗与停药相关的骨折风险：一项回顾性研究。

目的：评估地诺单抗停药后脆性骨折的发生率，并确定影响治疗依从性的因素。方法：回顾性分析2015年至2021年在Trakya大学骨质疏松症诊所接受denosumab治疗的3876例骨质疏松症患者的病历。总共有210名接受了至少两个常规剂量的denosumab的患者符合纳入条件。患者分为denosumab粘附型和denosumab非粘附型。依从性被定义为接受六个月的计划剂量，最大延迟达八周。结果：总体而言，124例（59.05%）患者为denosumab粘附性患者，86例（40.95%）患者为denosumab非粘附性患者。在32例患者中发现了新的脆性骨折：17例在denosumab粘附组，15例在denosumab非粘附组。无论患者的骨折史如何，两组在新发骨折的风险或类型上没有显著差异。结论：我们的研究结果表明，denosumab停药后的一些骨折可能源于骨质疏松症的自然进展，而不是反弹效应。尽管如此，仍应防止计划外的治疗中断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Croatian Medical Journal 医学-医学：内科

CiteScore

3.00

自引率

5.30%

发文量

105

审稿时长

6-12 weeks

期刊介绍： Croatian Medical Journal (CMJ) is an international peer reviewed journal open to scientists from all fields of biomedicine and health related research. Although CMJ welcomes all contributions that increase and expand on medical knowledge, the two areas are of the special interest: topics globally relevant for biomedicine and health and medicine in developing and emerging countries.